← SynDRA
LADUVIGLUSIB
SynDRA canonical compound SYN0008947 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | CDK1 | GSK3A | GSK3B | MAPK1 |
|---|
| Mechanism of action | glycogen synthase kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- CDK1 INHIBITOR
- GSK3A INHIBITOR
- GSK3B INHIBITOR
- MAPK1 INHIBITOR
- glycogen synthase kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- PAK5
- NEK4
- NEK6
- NEK7
- NTRK1
- NTRK2
- PAK1
- PAK4
- PAK6
- AKT1
- PASK
- PBK
- PDPK1
- PHKG2
- PIM1
- PIM2
- PIM3
- NEK2
- MYLK
- MKNK2
- MKNK1
- MAPK12
- MAPK13
- MAPK14
- MAPK15
- MAPK3
- MAPK8
- MAPK9
- MAPKAPK2
- MAPKAPK3
- MAPKAPK5
- MARK2
- MARK3
- MELK
- MET
- MINK1
- PKN2
- PLK1
- PLK3
Cross-references
Synonyms
- CHIR-99021
- CHIR-911
- CHIR99021
- CHR-00921
- CHR00921
- CT-99021
- CT99021
- FX03
- GSK-3 INHIBITOR XVI
- KIN001-157
- LADUVIGLUSIB (CHIR-99021)
- CHIR 99021
- CT 99021
- CHIR 911
- Laduviglusib [USAN]
- LADUVIGLUSIB [INN]
- CHEBI:91091
- Laduviglusib (USAN)
- RefChem:798393
- DTXCID50102422
- Laduviglusib (GMP)
- CHIR-99021 (CT99021)
- MFCD11846251
- CHIR 99021 Hydrochloride Salt
- GSK-3 Inhibitor XVI
- UNII-234CMT4GK4
- C22H18Cl2N8
- Kinome_3785
- Laduviglusib (Standard)
- SCHEMBL151139
- SCHEMBL240280
- GTPL8014
- orb1305728
- SCHEMBL29351682
- SCHEMBL29353709
- SCHEMBL29359162
- SCHEMBL29381114
- SCHEMBL29838591
- EX-A535
Look up LADUVIGLUSIB in the interactive SynDRA portal →